Cullinan Therapeutics registers Phase 1b/2a trial of velinotamig in ITP and wAIHA
The study will test subcutaneous velinotamig, a BCMA/CD3 bispecific antibody, in adults with relapsed/refractory immune thrombocytopenia and warm autoimmune hemolytic anemia.
Cullinan Therapeutics had one registry update for the week of July 31, 2026.
- A Phase 1b/2a, open-label study of velinotamig (also known as CLN-803, GR1803) is listed as not yet recruiting, with an estimated start of December 2026. The trial is an open-label dose escalation and dose expansion study of subcutaneously administered velinotamig for adults with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia, aimed at evaluating safety and tolerability.1 Enrollment is estimated at 72 participants1, and the drug is described as an engineered bispecific antibody directed against BCMA and CD3.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.